Paradigm Biopharmaceuticals Ltd (PAR)
Australian Securities Exchange · Australia · prices in AUD · close of 27 Oct 2026
Key indicators
| Last close | AUD 0.245 |
|---|---|
| 52-week range | 0.135 – 0.450 |
| Return, 1 month / 3 months | +0.0% / +44.1% |
| Return, 1 year / 3 years | −44.9% / −59.0% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 68.6% |
| Worst drawdown (1 year) | -67.8% |
| Average daily value traded | 0.37M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Paradigm Biopharmaceuticals is a pharmaceutical company based in Melbourne, Australia, that develops injectable pentosan polysulfate sodium, a medicine it is studying for painful inflammatory conditions. Its main focus is osteoarthritis of the knee, where it aims to reduce pain and improve joint function, and it also explores related uses such as bone marrow oedema and other musculoskeletal and inflammatory disorders. The company works with clinical investigators and regulators to run trials of its formulation, and its customers would ultimately be patients and the clinicians who treat them.
The shares are listed on the Australian Securities Exchange in Australia under the code PAR, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Paradigm Biopharmaceuticals Ltd (PAR) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.245 on 27 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 645 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 44.9% and over the last three months it rose 44.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.3% | ||
| From 52-week high | -44.9% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 44.1% | ||
| 6-month return | 28.9% | ||
| 12-month return, skipping the last month | -44.9% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 68.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -67.8% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.37M AUD | ||
| Zero-volume days | 45.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +44.1% |
| 6 months | +28.9% |
| 1 year | −44.9% |
| 3 years | −59.0% |
| 5 years | −86.5% |
Signals
| 50-day / 200-day average | 0.239 / 0.222 |
|---|---|
| Golden / death cross (60 days) | Golden, 8 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.003 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.